View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chapter 4.1<br />
188<br />
13. Seifer M, Hamatake RK, Colonno RJ, Standring D. In vitro inhibition of hepadnavirus polymerases<br />
by the triphosphates of BMS-200465 and lobucavir. Antimicrob Agents Chem<br />
1998;42:3200–3208.<br />
14. Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, et al. Efficacy of the carbocyclic<br />
2 0 -deoxyguanosine nucleoside BMS 200475 in the woodchuck model of hepatitis B virus<br />
infection. Anti microb Agents Chemother 1998;42:3209–3217.<br />
15. Colonno R, Medina I, Lamb C, Genovesi E, Clark J. Maintenance of viral suppression in chronically<br />
infected woodchucks with weekly dosing of BMS-200475. Hepatology 1998;28:488A.<br />
16. Colonno RJ, Genovesi EV, Median I, Lamb L, Durham S, Corey L, et al. Long-term therapy with<br />
entecavir (BMS-200475) in the wood chuck model of chronic hepatitis infection. Abstract 172<br />
of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,<br />
Canada, 2000.<br />
17. Tsiang M, Rooney JF, Toole JJ, Gibbs C. Biphasic clearance kinetics of hepatitis B virus from<br />
patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863–1869.<br />
18. Wolters LMM, Hansen BE, Niesters HGM, Zeuzem S, Schalm SW, de Man RA. Viral dynamics<br />
in chronic hepatitis B patients during lamivudine therapy Liver. 2002 Apr;22(2):121-6<br />
19. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Quantitative detection of<br />
hepatitis B virus DNA in two international reference plasma preparations. EUROHEP Pathobiology<br />
Group. J Clin Microbiol 1999;37:68–73.<br />
20. Stuyver L, van Geyt C, de Gendt S, van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line<br />
probe assay for monitoring during resis tance in hepatitis B virus-infected patients during<br />
antiviral therapy. J Clin Microbiol 2000;38:702–707.<br />
21. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral<br />
dynamics in vivo and the antiviral efficacy of Interferon-a therapy. Science 1998;282:103–107.<br />
22. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in<br />
hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398–4402.<br />
23. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Cruz de Castro E, Costa X, et al. Two years of<br />
lamivudine therapy in patients with chronic hepatitis B. Analysis of efficacy and emergence<br />
of HBV genomic variations (abstract). J Hepatol 2000;2(Suppl):111.<br />
24. Liaw YF, Leung NW, Chang TT, Guan R, Tai D, Ng K, et al. Effects of extended lamivudine<br />
therapy in Asian patients with chronic hepa titis B. Gastroenterology 2000;119(1):172–180.<br />
25. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment<br />
in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:<br />
results after 3 years of therapy. Hepatology 2001;33(6):1527–1532.<br />
26. de Man RA, Wolters LMM, Nevens F, Chua D, Sherman M, Lai CL, et al. A study of oral<br />
entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic<br />
hepatitis. Hepatology 2001;34(3):578–582.